Personalized therapeutics: HIV treatment in adolescents.
Rakhmanina
N Y
NY
Division of Infectious Disease, Children's National Medical Center/George Washington University School of Medicine and Health Sciences, Washington, DC, USA. nrakhman@cnmc.org
Capparelli
E V
EV
van den Anker
J N
JN
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy; D000293:Adolescent; D000367:Age Factors; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D044966:Anti-Retroviral Agents; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D014943:Global Health; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D020380:Needs Assessment; D010347:Patient Care Planning; D017410:Practice Guidelines as Topic; D011379:Prognosis; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014944:World Health Organization
D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D018894:Reverse Transcriptase Inhibitors